This preprint is under consideration at Journal of Cardiothoracic Surgery. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Liza Grosman-Rimon
Baruch Padeh Medical Center Poriya
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1456-6083
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Management of patients treated with ticagrelor is challenging, as stopping Ticagrelor prior to coronary bypass graft surgery (CABG) may increase the risk of acute stent thrombosis. The aim of the study was to compare bleeding complications in patients treated with ticagrelor combined with acetylsalicylic acid (ASA) until one day before surgery versus ASA alone.
Methods
Bleeding complications, defined as the composite of red blood cells transfusion ≥ 1000ml, chest drainage ≥ 2000ml, and bleeding requiring surgical re-exploration, were compared in 161 patients, 101 on preoperative acetylsalicylic acid (ASA) alone (group A) and 65 on ticagrelor + ASA (group B).
Results
There were no differences in bleeding complications between the two groups (26% vs. 27% in group A and B, respectively), with similar chest drainage in the first 24 hours (569 ± 393ml and 649 ± 427ml, respectively).
Conclusions
Continuing ticagrelor until coronary artery bypass surgery was not associated with increased bleeding complications, suggesting that with appropriate perioperative management, continuing ticagrelor until surgery may be safe.
Keywords
Ticagrelor, Bleeding, Coronary Artery Bypass Graft Surgery
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 17 Mar, 2021
Review #2 received
Received 16 Mar, 2021
Review #1 received
Received 09 Mar, 2021
Reviewer #2 agreed
On 07 Mar, 2021
Reviewer #1 agreed
On 06 Mar, 2021
Reviewers invited
Invitations sent on 06 Mar, 2021
Review #? received
Received 06 Mar, 2021
Editor assigned
On 04 Mar, 2021
Submission checks complete
On 04 Mar, 2021
Editor invited
On 04 Mar, 2021
First submitted
On 04 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Journal of Cardiothoracic Surgery. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Liza Grosman-Rimon
Baruch Padeh Medical Center Poriya
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1456-6083
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 17 Mar, 2021
Review #2 received
Received 16 Mar, 2021
Review #1 received
Received 09 Mar, 2021
Reviewer #2 agreed
On 07 Mar, 2021
Reviewer #1 agreed
On 06 Mar, 2021
Reviewers invited
Invitations sent on 06 Mar, 2021
Review #? received
Received 06 Mar, 2021
Editor assigned
On 04 Mar, 2021
Submission checks complete
On 04 Mar, 2021
Editor invited
On 04 Mar, 2021
First submitted
On 04 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Management of patients treated with ticagrelor is challenging, as stopping Ticagrelor prior to coronary bypass graft surgery (CABG) may increase the risk of acute stent thrombosis. The aim of the study was to compare bleeding complications in patients treated with ticagrelor combined with acetylsalicylic acid (ASA) until one day before surgery versus ASA alone.
Methods
Bleeding complications, defined as the composite of red blood cells transfusion ≥ 1000ml, chest drainage ≥ 2000ml, and bleeding requiring surgical re-exploration, were compared in 161 patients, 101 on preoperative acetylsalicylic acid (ASA) alone (group A) and 65 on ticagrelor + ASA (group B).
Results
There were no differences in bleeding complications between the two groups (26% vs. 27% in group A and B, respectively), with similar chest drainage in the first 24 hours (569 ± 393ml and 649 ± 427ml, respectively).
Conclusions
Continuing ticagrelor until coronary artery bypass surgery was not associated with increased bleeding complications, suggesting that with appropriate perioperative management, continuing ticagrelor until surgery may be safe.
Loading...